Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 13/20 | 0.66 |
| ▸ | JAK2 | O60674 | 4/20 | 0.59 |
| ▸ | JAK3 | P52333 | 4/20 | 0.59 |
| ▸ | AXL | P30530 | 1/20 | 0.58 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3209167 | 0.99 | PAK1 (0.65) | PAK1JAK2JAK3AXLTNIK | |
| SCHEMBL3210186 | 0.95 | PAK1 (0.61) | PAK1JAK2JAK3AXLTNIK | |
| Sulfuric Acid SCHEMBL3209435 | 0.95 | PAK1 (0.61) | PAK1JAK2JAK3AXLTNIK | |
| SCHEMBL3207950 | 0.92 | PAK1 (0.57) | PAK1JAK2JAK3AXLTNIK | |
| SCHEMBL13485402 | 0.90 | JAK2 (0.73) | PAK1JAK2JAK3AXLTNIK | |
| SCHEMBL13535840 | 0.89 | JAK3 (0.63) | PAK1JAK2JAK3AXLEGFR | |
| SCHEMBL3208957 | 0.89 | CCNA2 (0.60) | PAK1JAK2JAK3TNIK | |
| Hydrochloric Acid SCHEMBL3205555 | 0.88 | CCNA2 (0.59) | PAK1JAK2JAK3TNIK | |
| SCHEMBL14071057 | 0.88 | PAK1 (0.56) | PAK1JAK2JAK3AXLTNIK | |
| SCHEMBL13485395 | 0.88 | PAK1 (0.55) | PAK1JAK2JAK3AXLTNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590932-B1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY INC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20210070715-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2021-03-11 | — | — | US | disclosed |
| US-10752594-B2 | JAK1 and ALK2 inhibitors and methods for their use | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| EP-2970205-B1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | TOLERO PHARMACEUTICALS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20190119221-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10202356-B2 | JAK2 and ALK2 inhibitors and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20160214944-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160214944-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2016-07-28 | — | — | US | disclosed |
| WO-2014151871-A9 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | TOLERO PHARMACEUTICALS, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014151871-A2 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | TOLERO PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | TOLERO PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | TOLERO PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010011349-A2 | PYRIMIDINE-2,4-DIAMINE JAK2 KINASE INHIBITING ANTI-INFLAMMATION USE | SUPERGEN, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011349-A2 | PYRIMIDINE-2,4-DIAMINE JAK2 KINASE INHIBITING ANTI-INFLAMMATION USE | SUPERGEN, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| EP-2121634-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SuperGen, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008106635-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106635-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070715-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | PAK1 808/4885JAK2 2/4885JAK3 7/4885 |
| US-20160214944-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | PAK1 1135/4885JAK2 2/4885JAK3 7/4885 |
| US-20190119221-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | PAK1 808/4885JAK2 2/4885JAK3 7/4885 |
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | JAK2, JAK1, IRAK4 | PAK1 256/4885JAK2 1/4885JAK3 5/4885 |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | JAK2, JAK1, JAK3 | PAK1 201/4885JAK2 1/4885JAK3 3/4885 |
| US-10202356-B2 | JAK2 and ALK2 inhibitors and methods for their use | ALK, JAK2, JAK1 | PAK1 808/4885JAK2 2/4885JAK3 7/4885 |
| US-10752594-B2 | JAK1 and ALK2 inhibitors and methods for their use | ALK, JAK1, JAK2 | PAK1 660/4885JAK2 3/4885JAK3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.